The LifeBridge 10000 offering is now closed and is no longer accepting investments.

LifeBridge 10000

Breakthrough Cancer Therapy

Regulation Crowdfunding
Longwood, FL
Biotechnology
Accepting International Investment
Play video

"Because They Have More Life To Live"

LifeBridge 10000

The LifeBridge 10000 story began with the effort to save one life and the discovery to extend the life of millions. 


Laurie M. Travers had struggled with stage 4 breast cancer through nine reoccurrences over a period of 15 years. By late 2012, she had developed severe cancer in the pleura around the lung. The fluid buildup in the pleura was compressing her left lung, making it difficult to breathe. Every three weeks, Laurie had fluid withdrawals from the pleura (Thoracentesis) of between 900 and 1,500 cc. Laurie’s cancer had become reoccurring and non-responsive to most treatments. Laurie and her family thought the end was imminent.


During this time, Laurie's husband Peter heard of the new Tumor Treating Fields therapy approved by the FDA for Glioblastoma. He quickly learned it would not be available for people like Laurie for 10 or more years. Determined to help his wife, Peter formed a team of friends and family, including a senior engineer he met through church. After intensive work for hundreds of team hours, a new TTF device meeting the standards of present research was completed.


Shortly thereafter, Laurie had her sixth Thoracenteses, which produced 900 cc of fluid. The next day, Laurie began wearing the new TTF device at least 12 hours per day while continuing her chemotherapy. Three weeks later, her seventh Thoracenteses produced only 500+ cc; the eighth, 240cc; and the ninth only negligible fluid was found. The cancer in the pleura had been resolved. During this entire time, Laurie’s tumor markers increased, indicating the cancer was spreading, which did not make sense in light of the improvement. More scans were ordered.

The scans revealed that new cancer had broken out on the top of the liver. The chemotherapy was called a failure and a new one was started. The team immediately produced a second TTF array over the top of the liver and Laurie continued wearing the TTF 12 hours per day. The TTF had no side effects other than very minor skin irritations. Laurie returned to work as a neonatal nurse in between chemo cycles and taught a young women's bible study at church.


Over the next months, the tumor markers continued to increase, so additional scans were ordered. These scans showed continued stability in the pleura and a reduction in the tumors at the top of the liver where TTF had been applied. However, new tumors were now growing in the lower section of the liver, outside the range of the TTFs. The second chemo was also declared a failure. The liver TTF array was extended downward to cover the entire liver and a third chemo was started.

Laurie’s quality of life remained high as the third chemo was attempted. The same pattern continued and after several months, the higher tumor markers required additional scans. This time, the results showed a game-changing situation.


Cancer reduction and stability in the liver and pleura were noted, but new growth had broken out in the peritoneal cavity between the liver and lung TTF arrays. For the first time, we had reached the limits of static TTF therapy. A new array was needed over the peritoneal cavity, but was not possible because arrays cannot be placed on top of other arrays. TTFs can be too weak to kill cancer around the edges of arrays—central targeting is needed to maximize killing power.

 

This left Peter and his team with the excruciating decision of which cancer to treat and which to let grow. This was the beginning of the end for Laurie. For the next 12 to 18 months, wherever the TTF was applied, stability or reduction of the cancer occurred, while the spread of the disease continued outside the range of the TTF’s.


With two senior engineers on the team, Peter’s group began inventing a better way to deliver TTF. During the new system development, Laurie began taking a promising chemotherapy that was beginning to show tumor marker reductions. She elected to only take the heavy chemotherapy and forgo wearing the partially developed new version of TTF. Within two-and-a-half months, she could no longer tolerate the chemotherapy and began missing doses. Laurie passed away surrounded by family in May of 2016.

 

Laurie lived an additional three years from the time of severe cancer in the pleura. One year in, she had a “Sweet 16” celebration, giving thanks for 16 years of cancer survival. Laurie expressed her feelings in a note to friends.


“Peter & I have spent the whole last week just in awe of God’s goodness & the love of friends. The joy of the celebration has lingered in our (heart emoji)’s. Considering how desperate life looked with each drain of my lung last year at this time - God’s miraculous turn-around is awesome. I feel so blessed to have been given more life to live -"


Inspired by Laurie’s life, the team at Lifebridge 10000 continues building a patent-pending LB10000 device, built from the ground up for late-stage cancer patients with metastatic disease in two or more locations on the body at once. No longer will those treating metastatic patients with TTF be left with the painful decision of what cancer to treat and which to let grow. 


LifeBridge 10000 is set up as a social enterprise. Investors must understand and agree that a percentage of profits will be given to patients who cannot afford treatment. In addition we will sell our therapy on a sliding scale, those less fortunate will be be given significant discounts. We believe we can help 10,000 late stage cancer patients in the next 5 to 7 years and still give our investors an outstanding return.


Please join our team by investing in our mission.


Peter F Travers

CEO

LifeBridge 10000, LLC


The Opportunity

Investment

$1.00 per Non Voting Memberships Interests│Minimum purchase $100 

When you invest you are betting the company’s future value will exceed $12,242,235.


Perks
(Please note all perks occur after the offering ends and where applicable, when treatment is available) 


$100+ A thank you letter from our CEO and the option to submit a poem for our "I Have More Life to Live" book of poems. Poems must be written in good taste. Poems can be submitted by a friend in your name. Poems from cancer survivors or loved ones of survivors or past warriors of cancer, will be given the best placement in the collection. Poems must be original and can be copyrighted by authors, but must include permission to LifeBridge 10000 to print and distribute the poem free of charge for promotion of cancer therapy development.  To be published, poems must be 500 words or less. Please submit in word using Times New Roman font at 15pts.  

$500+ Thank you posting, with "in honor of" photograph on a special permanent section on our web page. Honor a friend or loved one who died or is fighting cancer by placing their picture in this section of our webpage and the option to submit a poem for our "I Have More Life to Live"book of poems. Poems must be written in good taste. Poems can be submitted by a friend in your name. Poems from cancer survivors or loved one of survivors or past warriors of cancer will be given the best placement in the collection.

$1,000+ Each increment of $1,000 dollar purchase of stock will include a book of poems compiled from our investors entitled " I have more life to live" (4 color cover)  

$5,000+ Made Possible By "Your Name" Our business model includes giving a percentage of profits toward treatment to those who cannot afford the therapy. When you purchase stock at this level, we will place your name on a plaque on a wave generator that delivers TTF to fight cancer. It will read "This therapy is made possible by "Your names"" Up to 4 plaques per generator.

$25,000+ At this level 2 wave generators will be engraved with only your name  stating "This therapy is made possible by "Your names"

$50,000+ When you purchase stock at this level we will name a meeting room at our future headquarters after you and dedicate it to you or a survivor. Only 2 available.

$100,000 At this level 10 wave generators will be engraved with only your name  stating "This therapy is made possible by "Your names"  You will also receive a special copy of our book of poems signed by our entire team. 


"Because They Have More Life To Live"

What Has Been Accomplished So Far

LifeBridge 10,000 has raised approximately $290,000 in seed money ($189,000 through direct investment through DEC 2016 and an additional 60+k for engineering and patent expenses paid by founders prior to incorporation, and an additional $40k in 2017). Tumor Treating Fields has been shown effective in 20 different types of solid tumor cancers in pre-clinical studies. LifeBridge has begun exploratory conversations with international firms like CeramTec for production of transducer arrays. Icon PLC the fifth largest clinical research organization in the world. Emergo Group a leader in medical device registration with offices in over 20 countries. Nikoa an FDA approved manufacture.


Per the advice of counsel the patents for all TTF devices are held by a totally separate Intellectual Property Company called Loyalty Based Innovations, LLC, which is majority owned by our managing partner Peter F Travers. Loyalty Based Innovation, LLC, executed an exclusive, global, perpetual and  royalty free license to Comprehensive Innovations, LLC (Comprehensive Innovations, LLC is the majority owner of LifeBridge 10000, LLC.). Comprehensive Innovations LLC, in turn executed an exclusive,  global, perpetual and  royalty free license to LifeBridge 10000's, LLC.  The patents under the companies control were granted a 30 month  patent priority date in over 140 countries by the International patent examiners, through the patent Co-operation Treaty. We are patent pending in 36 countries for long term protection. The first E.U. country to finish examining our patent application was Luxembourg which granted a full 20 year patent. Recently the U.S. patent office granted a Notice of Allowance for the TTF patent under the companies control. 


 LifeBridge has built and successfully tested a proof of concept prototype of our device (see Video) And LifeBridge 10,000 is a full member of the University of Central Florida business incubation program.


Watch our proof of concept video here.

The ground work has been laid, all we need is you!

The Science

The Problem With Fixed Array TTF

Our Solution

What Makes Our Products Different

There are three major advances our device has over the present form of Tumor Treating Fields (TTF):


1. Late stage cancer patients often have metastatic disease in multiple locations in the body, such as the lung and liver at the same time. The present form of fixed array TTF has difficulty treating diffuse disease. Our device is built from the ground up for such patients. Thereby bringing TTF to a whole new class of patients.

2. Once fixed array TTF sets up its optimum firing configuration, it produces an uneven treatment field. That is some parts of the field are more effective at killing cancer than others. Under fixed array TTF the most therapeutic portion of the field cannot be moved without physically taking the device off the patient and replacing it in  new location. In late stage patients this ends up being a losing scenario as it becomes impossible to keep up with the diffuse growth of cancer. Our device the LB1000 can manipulate the most therapeutic portion of the TTF in real time making it better able to treat diffuse disease. 

3. One of the mechanism of action that enables Tumor Treating Fields to kill cancer cells is a phenomenon called dielectrophoresis. The more angles a cancer tumor is treated from, the more likely dielectrophoresis occurs. Our device is able to treat any given tumor with more angles than fixed array TTF.   


Compelling Investment Thesis

More Advanced Solution

Large Addressable Market

Our Mission

Tumor Treating Fields have already passed many phase 2 clinical trials, showing safety and efficacy, including Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, and Mesothelioma (source NovoCure pipeline). It is fully FDA approved for two types of cancers (Source - FDA press release Oct, 8, 2015 and article FDA Takes Notice of Anti-Cancer Device for Mesothelioma By: Jamie Iovino on May 19, 2017 MesotheliomaGuide.com) . Therefore, we do not believe those patients who have reached a stage we call reoccurring and non-responsive should be denied treatment. These patients are not responding to chemotherapies and are past radiation and surgery. These people will die without a robust and effective treatment. For these warriors we have built a business model that allows for medical tourism in countries with special access laws designed with them in mind. The design of our device reflects this custom business model to ensure solid profits to our investors which will allow us to treat more patients.

Features of the LB10000 Device


  • Device comprised of two main systems: an electric field generator and transducer arrays capable of dynamic reassignment of array elements
  • Arrays are placed on the patient’s body in many configurations
  • Arrays designed to last 1 to 2 years
  • Built-in GPS to track each device, auto shut-off synchronized with payment arrangements, cell phone and advanced analytics
  • Remote scan import and remote programming of firing configuration capability built into system
  • Custom firing sequence to correspond with Cat Scans of patients disease.
  • In person and video support of patient during therapy

The Cancer Market (Dilemma and Opportunity)

Proven growth potential…

The leader in fixed array TTF, a company called NovoCure, reported first quarter 2017 net revenues of $34.9 million, reflecting 167 percent growth versus first quarter 2016 and 15 percent growth versus fourth quarter 2016 (source NovoCure reports April 27, 2017 Novocure .com)

 

Strong Market Demand

The World Health Organization predicts a 65% growth in the number of new cancer patients over the next 15 years. This is primarily due to the aging population, and increase in global population. (source- Cancer Fact sheet WHO Media Center Feb 2017)

 

Attractive regulatory landscape 

“Right to Try” laws have passed in 37 states allowing treatment after a phase 1 clinical trial (source www.righttotry.org/faq ). For the first time in modern history a medical device can be made available to patients while completing phase 2 and 3 clinical trials. Many countries such as Canada (source)  have special access laws allowing terminally ill patients to get therapy. Over 1,250,000 Americans travel abroad each year for medical treatments fueling the medical Tourism Industry (source)

 

Growing acceptance of TTF 

Pfizer, Johnson and Johnson, other firms—have raised over $250,000,000 to make TTF the accepted 4th modality for cancer treatment (source), 158 million from IPO (source)

 

High levels of funding and solid exit potential

Leading competitors attracted $250 million in funding, and executed $158M IPO (sources- see above)

The world health organization reports that in 2012 there were 14 million new cases of cancer leading to 8.2 million deaths. Over the next 15 years that number is expected to increase by 65% to 22 million new cases with 13 million deaths

The Global market for oncology and supportive care grew at a rate of 11.6% in 2016 and is expected to reach 150 billion by 2020 Reported by Quintiles IMS Health     

Quintiles IMS Health Report Link

Offering Summary

Maximum 107,000 Non Voting Membership Interests ($107,000)

Minimum 10,000 Non Voting Membership Interests ($10,000)


Company
LifeBridge 10000, LLC
 

Corporate Address
University of Central Florida Business Incubator
1511 E State Rd 434 #2001,  Suite 238
Winter Springs, FL 32708

 

Description of Business
LifeBridge 10000 is an oncology company specializing in bringing promising and proven therapies to late stage patients. Thereby providing the chance for high quality extended life.
 

Type of Security Offered
Non Voting Membership Interests
 
Purchase Price of Security Offered
$1 
 

Minimum Investment Amount (per investor)
$100












LifeBridge 10000, LLC (the “Compnay”) is offering up to 107,000 Non Voting Membership Interests on a best efforts basis. The offering may continue until 90 days from SEC filing (which may be extended at our option) or the date when all the shares have been sold. The units will be priced at One Dollar ($1.00) per Membership Interest. The minimum investor purchase shall be 100 Membership Interests.

Our minimum target offering amount is Ten Thousand ($10,000) and the maximum is One Hundred Seven Thousand Dollars ($107,000). If we reach the target offering amount of $107,000 we may amend the target amount, and after providing additional documentation, continue with a larger target. We may do this multiple times up to $1,070,000 in the calendar year 2017.

Generally, the aggregate purchase price of the shares you buy in this offering may not exceed ten percent (10%) of your annual income or net worth. Different rules apply to accredited investors and non-natural persons. We encourage you to review Rule 227 of Regulation Crowdfunding before you make any representation that your intended investment does not exceed applicable thresholds. For general information on investing we encourage you to refer to www.investor.gov.

There is currently no trading market for our shares and we cannot guarantee that such a trading market for our common stock will ever exist. Please see “Transferability of Securities.

Perks (Please note all perks occur after the offering ends and where applicable, when treatment is available

$100+ A thank you letter from our CEO and the option to submit a poem for our "I Have More Life to Live" book of poems. Poems must be written in good taste. Poems can be submitted by a friend in your name. Poems from cancer survivors or loved ones of survivors or past warriors of cancer, will be given the best placement in the collection. Poems must be original and can be copyrighted by authors, but must include permission to LifeBridge 10000 to print and distribute the poem free of charge for promotion of cancer therapy development.  To be published poems must be 500 words or less. Please submit in word using Times New Roman font at 12pts.  

$500+ Thank you posting, with "in honor of" photograph on a special permanent section on our web page. Honor a friend or loved one who died or is fighting cancer by placing their picture in this section of our web page and the option to submit a poem for our "I Have More Life to Live" book of poems. Poems must be written in good taste. Poems can be submitted by a friend in your name. Poems from cancer survivors or loved one of survivors or past warriors of cancer will be given the best placement in the collection  .

$1,000+ Each increment of $1,000 dollar purchase of stock will include a book of poems compiled from our investors entitled " I have more life to live" (4 color cover)  

$5,000+ Made Possible By "Your Name". Our business model includes giving a percentage of profits toward treatment to those who cannot afford the therapy. When you purchase stock at this level, we will place your name on a plague on a wave generator that delivers TTF to fight cancer. It will read "This therapy is made possible by "Your names" " Up to 4 plaques per generator.

$25,000+ At this level 2 wave generators will be engraved with only your name  stating "This therapy is made possible by "Your names"

$50,000+ When you purchase stock at this level we will name a meeting room at our future headquarters after you and dedicate it to you or a survivor. Only 2 available. In addition your Shares will be issued as voting shares.

$100,000+ At this level 10 wave generators will be engraved with only your name  stating "This therapy is made possible by "Your names"  You will also receive a special copy of our book of poems signed by our entire team.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments and salary made to one's self, a friend or relative; Any expense labeled "Administration Expenses" that is not strictly for administrative purposes; Any expense labeled "Travel and Entertainment"; Any expense that is for the purposes of inter-company debt or back payments.

Show More
Most recent fiscal year-end:
Prior fiscal year-end:
Total Assets
$2,519.00 USD
$989.00 USD
Cash And Cash Equivalents
$404.00 USD
$989.00 USD
Accounts Receivable
$0.00 USD
$0.00 USD
Short Term Debt
$0.00 USD
$0.00 USD
Long Term Debt
$0.00 USD
$0.00 USD
Revenues And Sales
$0.00 USD
$0.00 USD
Costs Of Goods Sold
$0.00 USD
$0.00 USD
Taxes Paid
$0.00 USD
$0.00 USD
Net Income
-$160,565.78 USD
-$26,519.92 USD

Risks

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.


Updates

Thank you for investing in our mission! Campaign ends at midnight tonight pacific time.

about 1 year ago

Thank you so much for investing in our mission. We are working hard for you as we believe serving our investors is of equal importance to serving those who need a new cancer therapy. You the investor drive development and the saving of lives. Those of you who are still considering joining our effort by investing, please note the campaign closes at midnight tonight.

Please let me know if you have any questions.

Thank you

Peter

“Because they have more life to live”
Peter F Travers
CEO
LifeBridge 10000, LLC
www.lifebridge10000.com

Thank you for investing in our mission! Campaign ends at midnight tonight.

about 1 year ago

Thank you so much for investing in our mission. We are working hard for you as we believe serving our investors is of equal importance to serving those who need a new cancer therapy. You the investor drive development and the saving of lives. Those of you who are still considering joining our effort by investing, please note the campaign closes at midnight tonight.

Please let me know if you have any questions.

Thank you

Peter

“Because they have more life to live”
Peter F Travers
CEO
LifeBridge 10000, LLC
www.lifebridge10000.com

Let’s end this campaign by giving someone the possibility of extended high quality life today, through Tumor Treating Fields (TTF)!

about 1 year ago

 https://clinicaltrials.gov/ct2/show/NCT02973789?term=lunar

Above is a picture from NovoCure’ s open phase 3 clinical trail for Non-Small Cell Lung Cancer (NSCLC). We are working hard to develop an advanced form of TTF that is not only more effective, but is designed from the ground up to treat late stage patients with disease in multiple locations, such as the lung and liver simultaneously. One of our main goals is to bring the therapy to these people who would otherwise not benefit.

But, there are hundreds of thousands of patients that can benefit from fixed array TTF. According to the American Cancer Society over 150,000 Americans will die from NSCLC this year, and even larger numbers worldwide.  You may be able to help some of them now. If you know of someone with NSCLC please share the link above to NovoCures trial at ClinicalTrials.gov. NSCLC patients working with their doctors can see if they qualify for this important 500-person phase 3 clinical trial. Those that received TTF and followed regimen in the phase 2 trial, fared over a hundred percent better than those on chemo alone.

If you can share this information and someone gets in the NovoCure trail and receives high quality extended life, you will understand the mission of LifeBridge 10000 in a new and personal way.

Peter Travers
CEO
LifeBridge 1000   

The progress you have helped make possible during our campaign! 2 days left to join the team

over 1 year ago


During our time together on StartEngine your funds have helped us:

  • Make medical history by demonstrating a small 16 array prototype manipulating a tumor treating field through a human body. This first time this had ever been done.
  • Tell the story in a proof of concept video (available on StartEngine).
  • Supplied our engineers with the parts they needed to expand our prototype.
  • Helped us finalize our U.S. patent work and receive a full U.S. patent. We are so thankful for this major milestone
  • Helped us reach the final stages of a prototype large enough to treat lung cancer! (picture shown)
  •   And you saw us expand our experienced advisory board. Combined we have 225 years of experience in the medical field, 8 startups 5 of which sold to larger concerns, 2 are ongoing businesses. Our advisors are on the boards of 7 companies and are named on 37 issued patents.

You can make a difference. Invest today!

Peter F Travers
CEO


We know firsthand how devastating cancer can be. Help us make a difference. Invest today! Only 3 days left

over 1 year ago

Your investment dollars at work. Your prototype large enough to treat lung cancer.

over 1 year ago

As we speak our engineers are putting our new prototype through its paces. This prototype is larger than fixed array devices being tested on over 500 lung cancer patients in open phase 3 clinical trials.

Our device is built from the ground up to bring tumor treating field therapy to late stage patients with disease in multiple locations like the lung and liver simultaneously. You can help us get to clinical trials by investing today!  Thank you on behalf of those who have more life to live!  Only days left.

Peter Travers

CEO

LifeBridge 10000, LLC

   

Learn how YOU are revolutionizing the development of cancer therapies. Watch our new video now!

over 1 year ago

LifeBridge 10000 raises $69,000 to reach a total to date of over $359,000

over 1 year ago

We have been asked “What if you don’t raise your highest goal on StartEngine?”. LifeBridge began raising funds through a Reg D offering before beginning on StartEngine. Although we are moving our emphasis to title 3 crowdfunding, friends family and accredited investors have continued supporting our research and mission. In January of this year $50,000 came in through our Reg D offering (see below). With your investment and additional commitments, we are approaching a total of $400,000 raised.

Our desire to move to crowd funding is our belief that you are more likely to be missional moving forward. You are OK with making a decent return and giving a percentage of profits to those who cannot afford treatment. We believe our mission will bring us all more profit as we gain the respect of the medical community as a company that cares. The bottom line is our effort will continue with or without crowdfunding. We hope and pray it will be with you, as institutional investors tend to strip away mission.

Please invest today, because they have more life to live! 

As you know the patented device of LifeBridge 10000, LLC is about the next advanced use of Tumor Treating Fields, but listen to what Mad Money CNBC says about the base science developed by NovoCure

over 1 year ago

                     Link to Mad Money CNBC:     https://www.youtube.com/watch?v=0qAlyZhfetc

Let me tell you a story of how tumor treating fields can change the management of stage 4 cancer over a life span.

over 1 year ago

My wife presented in front of our radiation oncologist with significant back pain from her stage 4 cancer attacking nerves in her lower back. We had run out of chemo’s to use, so radiation was the only known way to keep the pain from becoming debilitating. My wife’s medical chart was still on paper at this point and was literally about 10 inches thick. 18 years and twelve re-occurrences of cancer made for a long history.

The doctor read silently, searching the file when a disappointing look came over his face. He said “about twelve years ago you had a breakout of cancer in your lower back and we used multiple treatments of radiation to resolve the issue. The pain you are experiencing now is in the same area. If we radiate that area again it could damage your nerves and the pain could be much worse. We should only radiate as a last resort”. Out of options is the dreaded destination of the cancer journey, but for us there was good news.

Before we get to the good news, let’s talk for a moment about a lifetime strategy for battling cancer. We learned through my wife’s 18-year battle with stage 4 breast cancer that you are going in to fight with a limited amount of ammunition. Once a certain type of ammunition is used up, you can be left without a defense. Some chemo’s have a lifetime limit to how many doses you can take, because the side effects can put you into a wheel chair or worse. As we learned above, radiating the same area twice is really discouraged, because of the nerve damage and other side effects.   

One of the problems with managing cancer is that many times it is managed from 1 re-occurrence to the next without a lifetime strategy. To be fair, that is because there have not been many options for developing a long-term plan. My wife is an example of how Tumor Treating Fields can bring about a new strategy. The day the doctor told us he did not recommend radiating Laurie’s back a second time, he also shared with us the location of the tumors causing the pain. That same day our team began building a new tumor treating field array to cover the area. One for the lower back and one in the front to create the tumor treating field. We called it the bikini array.

Within two weeks of wearing the new array the pain began to subside. Within a month the pain was gone. Tumor treating fields allowed Laurie to avoid a risky treatment. That is the point. Tumor treating fields can be used to create a long-term strategy of preserving various treatments for later use if needed. Here is another example.

Years earlier Laurie had a suspicious tiny spot on her pancreas. To biopsy it would be difficult. The procedure would require going down the throat, out the stomach, capture the sample and back out. Obviously, the doctors wanted to avoid the ordeal. So, we were asked to wait. Almost 3 full months later scans showed that the spot had gotten bigger and the biopsy was ordered. The results showed cancer. One of the most effective chemo’s was used to eliminate the tumor. Not only did Laurie have to lose her hair and go through yet another ordeal, but one our most powerful pieces of ammunition was used up. Years later when Laurie needed it more, it could not be used effectively.

If tumor treating fields were available there is a high probability we would not have had to wait those three months. The tiny tumor could have been eliminated by tumor treating fields and one of the most effective chemo’s could have been saved for later, if needed at all. Not to mention saving Laurie from going through another rough round of side effects. Tumor treating Fields have no side effects to date, only minor skin irritation. Here we are years later and fixed array tumor treating fields for pancreatic cancer is entering a phase 3 clinical trial, after proving to be over a 120% more effective than chemotherapy alone in a phase 2 trial.

Tumor treating fields can potentially change the way long term cancer is managed. Using it against new tumors when they are tiny. Not only does this avoid terrible side effects that strain the patient and whole family, but it preserves lifesaving therapies for later if needed.  

You are the key, make a difference today by investing, because they have more life to live!

Thank you for your time, please let me know if you have any questions.

Peter Travers

CEO

LifeBridge 10000, LLC

  

The Orlando Sentinel published an article today about our work. Please pass it along

over 1 year ago

30 Days left. Let’s finish strong for those who have more life to live!

over 1 year ago

In the days ahead, you will receive:

  • A true story illustrating how Tumor treating Fields can change the long-term strategy for managing cancer over a lifetime  
  •  A short whiteboard video illustrating how our business model can revolutionize how cancer therapy is developed, potentially saving hundreds of thousands of lives.
  • A video showing our advanced new prototype large enough to treat lung cancer.

More to come. Please share our opportunity with your friends.

Thank you for your investment. We are working hard for you and those who have more life to live.

Peter

“Because they have more life to live”
Peter F Travers
CEO
LifeBridge 10000, LLC
www.lifebridge10000.com

Getting Closer!

over 1 year ago

Here is an array of 20 tumor treating field discs ready for programing in our testing prototype. Each disc is its own computer. Each has its own name (address) and can be called upon to act in unison with any other combination of discs. This means maximum flexibility to target multiple tumors. This is what our patents are all about.

This is the technology that will make tumor treating field therapy available to late stage patients. We are building for them, because they have more life to live. Join our mission by Investing today!

Peter

“Because they have more life to live”
Peter F Travers
CEO
LifeBridge 10000, LLC

Your Investment Dollars at Work!

over 1 year ago

The next level Tumor Treating Field prototype is on the bench ready for final assembly and testing. The prototype will be large enough to treat lung cancer. The information we gain from testing this level of device will drive us toward our production prototype. We will present that device to the FDA to request our Investigational Device Exemption (IDE) which is required for all medical devices of our class. The step after that is a proof of concept human trial where we will be able to treat actual patients. Your dollars are helping us move closer to helping those who have more life to live. Invest today!

Peter Travers

CEO

New video sharing our story- One of her favorite sayings became "stop trying to run from the storm and learn to dance in the rain" Click photo below

over 1 year ago

What is your number 1 question?

over 1 year ago

38% of our followers have already invested (51 of 133). We are told this is excellent? Our average investment is nearly 4 times the minimum required, another good sign. We hope this means we are communicating well and faithfully, but we want to do better. Would you please help us by asking questions in the comment section? We would love to hear from you!

Sincerely

Peter

“Because they have more life to live”
Peter F Travers
CEO
LifeBridge 10000, LLC
www.lifebridge10000.com

Your Investment Dollars at work - Help us move closer to offering high quality extended life to late stage cancer patients

over 1 year ago

Your investment dollars are helping us finish the next phase of our Tumor Treating Field device. Ken Watkins oversees Matt Travers (Laurie’s son if you have read our story) as he assembles the disc arrays for our next working prototype large enough to treat lung cancer.

As a former Electrical Engineering Manager at Northrop Grumman, Ken was responsible for overseeing the work of 30 electrical engineers. As one of our founders Ken’s commitment and faithful work inspires us, as he often does something with our device 6 days a week.

Thank you for your investment and if you haven’t joined our team yet please invest today!

Sincerely

Peter

 

“Because they have more life to live”

Peter F Travers

CEO

LifeBridge 10000, LLC

www.lifebridge10000.com

Notice of Funds Disbursement

over 1 year ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, LifeBridge 10000 has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in LifeBridge 10000 be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

To us, serving you is the same as serving those who have more life to live!

over 1 year ago

This week I had the privilege of answering highly relevant questions from one of you. The result was an exchange that can benefit everyone and ended in a follower becoming an investor. You can read the exchange in the comment section.

How about you? Our campaign now has 119 followers 47 of whom have invested. That leaves 72 of you who may have questions. How can I help? Let’s talk. Please let me know your questions or concerns. We have a broad team and a lot of expertise. I hope you will give us the opportunity to address your concerns.

To us, serving you is the same as serving those who have more life to live!

 Sincerely

Peter

“Because they have more life to live”

Peter F Travers

CEO

LifeBridge 10000, LLC

www.lifebridge10000.com

A Special Christmas Gift That Can Relieve Suffering

over 1 year ago

 Although our U.S, Patent issued on Dec 5th, it was special indeed to get the official copy in the Christmas mail. It’s a hard-earned gift that took thousands of hours of hard work to bring into existence. Our dedicated team of engineers and you our investors made it possible.

With your investment we are confident in our ability to extend high quality life to cancer patients. I am often asked if patients will wear our device even though it has no significant side effects. It does seem a task to wear the device each day.

 What we learned through my wife’s pioneering experience...(continued below)


is that in most cases our therapy relieves or prevents suffering. When she had cancer in the pleura around her left lung, breathing was difficult and getting worse. After wearing our device, her breathing steadily improved and after 9 weeks she breathed freely. This year the FDA gave humanitarian approval for Tumor Treating Fields to treat Plural Mesothelioma. The frequency and configuration approved by the FDA matches exactly was given to my wife in 2013.  

Cancer in her liver was cleared twice which prevented the taking of harsh chemo therapies. Her cancer began attacking the nerves in her lower back. The doctors where reluctant to administer radiation because the area had been radiated years before. Our device was applied to the area and her discomfort was resolved without radiation.  

If you haven’t already you can make your most impactful investment of the year right now. Join our team by investing today!

Peter

“Because they have more life to live”

Peter F Travers

CEO

LifeBridge 10000, LLC

www.lifebridge10000.com

 

Why we are extending our campaign

over 1 year ago

Hello fellow LifeBridge Builders. I hope its OK to call you that, because that is what you are! Your investment is moving us toward being able to offer a viable cancer therapy to those wonderful warriors who have fought the brave fight, but are out of options. We can provide them extended high quality life through our patented therapy. Together we can be a LifeBridge to those who have more life to live!

We are extending our campaign because:

  • We have been interviewed by the health reporter from the Orlando Sentinel. The editor has approved the writing of an article for us which likely to mention our StartEngine campaign. The article will have a circulation of 150,000, plus online activity. This article will not come out until January or February of 2018. We did not want to close our campaign and have the article go to waste.
  • Like wise we have been interviewed by the Orlando Medical News. This publication has 5,000 paper subscribers and 5,000 online, for a total of 10,000 doctors, nurses and medical executives. This article is also to mention our StartEngine campaign and is to come out in January. We did not want to lose the advantage of this public relations by closing the campaign at the end of the month.
  • The University of Central Florida business Incubator of which we are a member has provided us with a public relations firm who is seeking additional PR exposure for us in the first quarter of 2018. Extending our campaign will help us get the most advantage from this effort.
  • Dr Zehngebot (See team) is working on a brief video talking about Tumor Treating Fields which will be ready the first quarter of 2018.
  • In addition, we are planning on releasing a video by February on the 5th advantage of investing in LifeBridge 10000. Revolutionizing Cancer Therapy Development.
  • As we speak our preproduction prototype, large enough to treat lung cancer, is under construction. We plan on releasing a video show casing the device before the end of our extended campaign.

Thank you so much for your on-going support. If you have not yet joined the team, please consider doing so by investing today. We are in this for years to come and hope you will help us serve those who have more life to live!

Peter

“Because they have more life to live”

Peter F Travers

CEO

LifeBridge 10000, LLC

www.lifebridge10000.com

Amending our Securities Offering

over 1 year ago

Hello! Recently, a change was made to the LifeBridge 10000 offering. Here's an excerpt describing the specifics of that change:


Extending campaign for 90 days to 3/28/2018


When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Thanks to you…

over 1 year ago

Our dedicated engineers, (see team) believe in our work so much that they work under deferred compensation. This means your investment dollars go for vital parts and essential items needed to move our mission forward.

Thanks to you, our engineering team confirmed this morning that we are on track for a January 2018 completion of our advanced prototype. This is not just a proof of concept. The device will be large enough to treat lung cancer. It will deliver the same therapy that is presently being used in a fixed array phase 3 study of 500 patients. However, it will be much more controllable. That extra control can save the lives of patients with diffuse disease. That is what our patent is all about.

If preliminary testing is verified in the advanced prototype, the next version will be a full production model. This will allow us to begin the process of applying for our phase 1 clinical trial. A successful phase 1 trial is all that is needed in strategic countries to begin treating late stage patience. In addition, 36 U.S. States have Right to Try laws. These laws allow late stage patients to be treated after a successful phase 1 trial.

Thank you so much for your continued support on behalf of those who have more life to live! If you have not yet joined the team, please consider investing today.

Peter

“Because they have more life to live”
Peter F Travers
CEO
LifeBridge 10000, LLC
www.lifebridge10000.com


Notice of Funds Disbursement

over 1 year ago

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, LifeBridge 10000 has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in LifeBridge 10000 be on the lookout for an email that describes more about the disbursement process.


This campaign will continue to accept investments until its indicated closing date.


Thanks for funding the future.

-StartEngine

Thanking God! Our U.S. patent issued today Dec 5th, 2017

over 1 year ago

On behalf of those who have more life to live, I would like to give special thanks to all our supporters who helped us get our U.S. patent for treating multiple tumors in patients with metastatic disease, by electric fields. Issued today, Dec 5th, 2017!  If you haven’t joined our team yet, please do so by investing today! The patent is under the exclusive control of LifeBridge 10000, LLC.

Thank You

Peter

“Because they have more life to live”
Peter F Travers
CEO
LifeBridge 10000, LLC
www.lifebridge10000.com

Understanding the billion-dollar market for the LifeBridge Cancer therapy

over 1 year ago

In preclinical studies TTF treatment modality has been shown to be effective in treating 20 different types of cancer (Phases 1 – 4), however LifeBridge targets the late stage patient for three reasons:

  • The LB10000 is the only TTF device designed to treat late stage patients, with multiple disease sites
  • Patient’s are eligible to take advantage of “Right to Try” laws in the U.S.
  • These people need our help, they are running out of options                                                                                                                 


According to the American Cancer Society, there are presently 1.7MM cancer patients with 36 months, or less, to live in the U.S. The eligible patient treatment group is determined by the following analysis:

  • Most treatable: Of those 1.7MM patients, the cancers that are most treatable by TTF are Lung, Ovary, Pancreas, Breast, Uterine, Colon, Liver, Melanoma, Prostate and Urinary, as shown in preclinical, pilot, and phase 1 and 2 studies conducted by the leaders in the field.
  • Preferred age group: Patients that are between 20 and 75 years of age. The size of these age groups was determined by using data from the U.S. Census Bureau and cancer occurrence statistics from the American Cancer Society.

  • Life expectancy: Patients expected to live for less than 12 months were not included in the analysis even though they might benefit from the treatment.
                    

Using the above filters of Cancer types, age and life expectancy brings the number of TTF candidates down to 443,000 every 36 months. In annual terms this is roughly 147,000 late stage cancer patients who are presently dying each year without a viable therapy, that can be potentially helped by the LifeBridge device. The above analysis is for the U.S. only. Running the same analysis globally, the number of late stage patients that could be helped by TTF is roughly 2 million per year.

This vast need makes the market for the LifeBridge device in the billions of dollars annually. We believe we can make an excellent profit for you and help thousands in need who cannot afford the treatment. Please invest today!

Please let me know if you have any questions. 

“Because they have more life to live”

Peter F Travers

CEO

LifeBridge 10000, LLC

www.lifebridge10000.com

Great News! A Full U.S. Patent to Be Issued December 5, 2017

over 1 year ago

This is a huge boost toward being able to treat those who have more life to live… Help us get to market!

The breakthrough cancer therapy controlled exclusively by LifeBridge 10000, LLC will be granted a full U.S. patent on December 5, 2017. The news was posted on the U.S. Patent Office site this past week. A notice of allowance was posted on 08/23/2017. Posting an issue date means that all final drawings have been accepted and that all fees have been paid. The term of the patent is 20 years from the original filing date, which will protect our investors through June of 2035. The U.S. is now the 2nd country to grant a full patent for the LifeBridge device. The EU country of Luxembourg has also granted a full 20-year patent.

This is a huge boost toward being able to treat those who have more life to live. This kind of protection makes it easier to attract investment needed to advance our therapy. We believe we can get the needed credentials to begin a phase 1 clinical trial within 12 months of full funding. A phase 1 trial is needed to give doctors confidence that our advanced device is equally as safe as the present form of Tumor Treating Fields. The present form is already approved by the FDA for Plural Mesothelioma (humanitarian) and Glioblastoma (a deadly brain cancer). A successful phase 1 trial will open several foreign markets and 37 states under Right to Try laws.

The present form of Tumor Treating Field is not designed to treat late stage patients with disease in multiple locations, such as the lung and liver simultaneous. Our device was created for such patients. Your investment is helping us move closer to offering them our therapy. If you have not yet invested, please considering doing so today.

Please let me know if you have any questions.

Sincerely

Peter

 

“Because they have more life to live”

Peter F Travers

CEO

LifeBridge 10000, LLC

Going after Cancer: Reach and Targeted Intensity

over 1 year ago

The 4th reason the LifeBridge device is more effective than the present form of Tumor Treating Field (TTF) is:

4. Custom Reach and Intensity: Our ability to dynamically reassign array elements allows us to treat difficult to reach cancers. This also creates the ability to customize the intensity of the Tumor Treating Field with split second timing.

Fixed array TTF can be set up in almost any configuration. However, it is then immovable. Choosing to target a particular tumor, eliminates the possibility of treating another. This is not the case with the LifeBridge device. Our ability to dynamically reassign array elements allows us to vary treatment during therapy sessions. For example, suppose a doctor was concerned about a group of tumors on the liver. He decides to emphasize treatment to eliminate them, before they create significant life altering symptoms.

A treatment plan creating a higher density TT Field over the area could be worked into the firing sequence. By programing a smaller number of arrays to energize against a larger set. See below Fig 1 and 2

In addition, co-planar or half-moon fields can be formed when advantageous.


Thank you for your interest. Please become part of the solution by investing today. Updates to come: Revolutionizing the way cancer therapies are developed and the size of the TTF Market.

Peter

“Because they have more life to live”
Peter F Travers
CEO
LifeBridge 10000, LLC
www.lifebridge10000.com

Special Thanks to you!! Exceeding our minimum goal

over 1 year ago

Special thanks to those of you who have invested. You helped us exceed our minimum goal today! Please understand we are just as committed to serving our investors, as we are those who have more life to live. We see the two as equal. The better we serve our investors the more families we can help overcome the struggles of cancer.

Sincerely

Peter

“Because they have more life to live”
Peter F Travers
CEO
LifeBridge 10000, LLC
www.lifebridge10000.com

Expanding the Hope

over 1 year ago

The third reason the LifeBridge device is more effective than the present form of Tumor Treating Field (TTF) is our ability to control the most therapeutic portion of the TT Field (3 of 5-part series).

 3. Field Sweeping: Every TTF Field has 3 main parts. A most therapeutic center, a less therapeutic mid layer and a non-therapeutic outer layer. The following represents a simulation of a patient with isolated tumors in the left lung. The present form of TTF serves this patient well.

However, the following simulation shows diffuse disease. The present form of TTF would fail this patient.


Our ability to control the most therapeutic portion of a Tumor Treating Field will bring hope to hundreds of thousands of late stage patients as shown in this :35 second video.

If you have not invested yet, please help our mission by investing today. We believe we can provide an excellent return while helping cancer patients at the same time. Please let me know if you have any questions.

Thank you on behalf of those who have more life to live.

Peter

“Because they have more life to live”

Peter F Travers

CEO

LifeBridge 10000, LLC

www.lifebridge10000.com



Meeting with Dr. Zehngebot – More effective cancer therapy

over 1 year ago

This discussion may be a little complicated, but the graphics below should clarify the principles. The second reason we believe our LifeBridge device is more effective at reducing solid cancer tumors is (part 2 of a 5 part series) :

2. Dielectrophoresis: This is a phenomenon that kills targeted cancer cells faster than the main killing mechanism of TTF, which is called dipole alignment. I have included an illustration to show how dielectrophoresis works. If you can manage to target a TT field through the cleavage furrow (see below) during late stage cancer cell division, the cell disintegrates.

What this means is that the more angles you attack a tumor from, the more dielectrophoreses occurs. Pre-clinical research shows that adding a 2nd perpendicular angle of TTF field delivery, increases tumor reduction by as much as 20%. So, if you target a TT field from front to back you get one level of tumor reduction. If you alternate between front to back and side to side, you get a 20% increase in cancer cell death. In graphic form below is what the phenomenon is, what the present treatment offers and how the LifeBridge, LB10000 device can increase the killing power of a TT field.    



Dr. Zehngebot is the Director of Clinical Research at the Florida Hospital Cancer Institute and is on our advisory board (see team).  In January of 2018 Dr. Zehngebot is scheduled to begin exploratory conversations with University of Central Florida personnel regarding the design of a pre-clinical study. The study will be designed to test and document that the LifeBridge device reduces cancer tumors faster than traditional TTF, through the increased occurrence of dielectrophoresis.

If you have not yet invested, please consider doing so now. Getting over our minimum raise will allow more exposure for the remainder of the campaign. If you have invested, please know that we are committed to working as hard for your ROI as we are for those who have more life to live.

Sincere thanks!  

Peter

Please let me know if you have any questions

“Because they have more life to live”

Peter F Travers

CEO

LifeBridge 10000, LLC

www.lifebridge10000.com

5 ways your investment in LifeBridge 10000 advances the fight against cancer –

over 1 year ago

There are 5 ways your investment moves us toward more effective treatment of late stage cancer through the next generation of Tumor Treating Fields (TTF). In the days ahead, I would like to share them with you one at a time.

1. Dynamic reassignment of array elements. The present form of TTF uses fixed arrays. This makes it difficult to treat cancer in two or more locations, like the lung and liver simultaneously. Fixed arrays eventually make the therapy ineffective for advanced metastatic patients who need treatment the most. Our patented approach allows array elements to be shared (see below). This makes the therapy available to a whole new class of late stage patients. 

This advantage will allow us to go to market quickly, since we are doing what is already being done on patients with disease in one location, like lung cancer in the lungs only. For example, TTF has been shown safe and effective in very successful phase 1 and 2 clinical trials by the current leader in the field. These trials have been completed on patients with Ovarian, Pancreatic, and Non-Small Cell Lung Cancer. The present device can only handle one area of disease at a time.  All we are doing with our patented solution, is treating the same areas, in the same way, but with one device on single patients.

To illustrate further, if a person has cancer in the ovaries, pancreas and lungs at the same time, our one device can fire for each area. When we fire for the ovaries, it matches what has already been tested for on patients who only have ovarian cancer. When we fire for the pancreas, it matches what has already been tested on patients who only have pancreatic cancer. The same is true for the lungs.

Independent engineering reports can verify we are matching the therapies already tested. A phase 1 clinical trial of our own will allow doctors in many countries to begin treating patients with our device right away. In addition, there are 37 states that have “Right To Try” laws allowing late stage patients to access new therapies after a phase 1 clinical trial.  

Oncologists hate to tell patients to get their lives in order, because they are out of options. They are starving for legitimate, scientifically proven therapies for late stage patients. If you haven’t yet, please consider investing today. If you have already invested, please know that we are as committed to working for your ROI as we are for those who have more life to live. We believe the better ROI we can supply, the more patients we will be able to treat, offering high quality extended life. 

Please let me know if you have any questions.

Peter

 

“Because they have more life to live”

Peter F Travers

CEO

LifeBridge 10000, LLC

www.lifebridge10000.com

Announcing Completion of our next generation Tumor Treating Field Wave Generator

over 1 year ago

Scott Krywick and Ken Watkins have finished our next generation Tumor Treating Field Wave Generator and are setting it up for final testing. This wave generator is built sophisticated and powerful enough to drive a full body Tumor Treating Field array. It will be used to test a therapeutic array large enough to treat lung cancer, which is being built as we speak. This is a major step forward in our journey toward treating patients.

Scott Krywick (left) is presently a Manager of Software Engineering at Northrop Grumman. Northrop has given Scott permission to work on our project and is under contract with LifeBridge. Ken Watkins (right) is our Senior Engineer and one of the founders of LifeBridge 10000. He has over 40 years’ experience in developing new high-tech products. He held the position of Electrical Engineering Manager at Northrop Grumman Corp, where he was responsible for overseeing the work of 30 electrical engineers

With full funding our engineers will be able to proceed much faster than our present pace. If you have not invested yet please consider doing so as soon as possible. Please let me know if I can answer any questions.

Peter

“Because they have more life to live”
Peter F Travers
CEO
LifeBridge 10000, LLC
www.lifebridge10000.com

We don't have to make the excruciating decision

over 1 year ago

Our experience with my late wife Laurie taught us the hard way, that the present form of Tumor Treating Fields (TTF), emerging from the FDA approval process, fails the late stage patient. These men and women have disease in multiple locations, like the lung and liver simultaneously. The present form of TTF forces you to make the excruciating decision to choose what cancer to treat and what to let grow. Fixed array TTF gave my wife nearly three extra years of high quality life. She got to continue working as a neonatal nurse and was able hold her first grandchild. But when we had to start letting some cancer grow while treating others, it was the beginning of the end.   

Now there is a better way. We can treat cancer more effectively and in multiple locations. The late stage patient with metastatic disease does not need to be excluded. Here is a link to a shortened version of our proof concept video (-7 min) to illustrate how.

https://www.youtube.com/watch?v=BugSVIuVB94&feature=youtu.be

Thank you for your investment!

Peter

“Because they have more life to live”

Peter F Travers

CEO

LifeBridge 10000, LLC

www.lifebridge10000.com

Additional Patents

over 1 year ago

It’s been an exciting week for our mission. As our U.S. patent moves from notice of allowance, given in August, to full issuance, we have more innovations worthy of patenting. We have developed methods to allow our next generation Tumor Treating Field device to produce stronger more effective fields without increasing warmth. In addition, we have developed processes for targeting tumors for advanced patients, special free hand programing controls that allow the doctor to fine tune the device based on input from the patient. With the help of our patent attorney we are writing these patents up as we speak. With your help we can file these additional patents to help insure our ability to improve the therapy in the future. Again, thank you for support. Please tell your friends.

Peter

“Because they have more life to live”

Peter F Travers

CEO

LifeBridge 10000, LLC

www.lifebridge10000.com

1.7 Million Cancer Patients with 36 months or less to live. Of those 443,000 could potentially be helped by the next genration of TTF

over 1 year ago

Thank you so much for your investment and interest in bringing Tumor Treating Fields (TTF) to late stage cancer patients. Many of you may not know that our patented next generation TTF device is based on the same technology already approved by the FDA for Glioblastoma (Brain cancer), and has humanitarian FDA approval for Mesothelioma. Phase 2 trials have successfully completed for Ovarian, Pancreatic, and Non=Small Cell Lung Cancer with great success.

The problem is that none of the above research is targeted to the late stage patients with metastatic disease in two or more places like the lung and liver at the same time. In fact, the current TTF clinical trial pipeline doesn’t even list such patients. Their device is just not designed to work for late stage patients. We are building from the ground up for just such patients.

According to the American Cancer Society, there are presently 1.7MM cancer patients with 36 months, or less, to live in the U.S. After filtering for types of cancer, age and life expectancy the number of patients that could be potentially helped by our patented Tumor Treating Field device is 443,000. It keeps us up at night. Thank you so much for your interest and investment.

Peter

“Because they have more life to live”
Peter F Travers
CEO
LifeBridge 10000, LLC
www.lifebridge10000.com

Comments ({{profileCtrl.startup.comments_count}} total)

{{profileCtrl.newComment.body.length}}/2500
Show More Comments